Jason Gunn
Critical Care Medicine · Charleston, SCNPI 1386760080
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations.
Across 51 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Electromed, Inc.$174
- Axsome Therapeutics, Inc.$171
- GSK$101
- Inspire Medical Systems, Inc.$80
- Harmony Biosciences LLC$79
- Genentech USA, Inc.$45
- plus $213 from 12 others
Across 8 payments — averaging $26,960 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$216K
What the payments were for
- Food & beverage$864100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Electromed, Inc. | 17 | $174 |
| Axsome Therapeutics, Inc. | 6 | $171 |
| GSK | 6 | $101 |
| Inspire Medical Systems, Inc. | 2 | $80 |
| Harmony Biosciences LLC | 3 | $79 |
| Genentech USA, Inc. | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Inogen, Inc. | 3 | $21 |
| Intuitive Surgical | 1 | $20 |
| Inari Medical, Inc. | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $17 |
| Itamar Medical Inc | 1 | $17 |
| Gilead | 1 | $17 |
| Baxter Healthcare | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $11 |
| Advanced Respiratory, Inc | 1 | $11 |
| Mylan Specialty L.p. | 1 | $11 |
How this compares
$864 in reported general payments places this provider in the 60th percentile of 93 critical care medicine providers in South Carolina.
See all critical care medicine providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 15 | $294,544 |
| XolairOmalizumab | 39 | $197,571 |
| OpsumitMacitentan | 11 | $138,433 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $95,767 |
| Spiriva RespimatTiotropium Bromide | 46 | $30,545 |
| SunosiSolriamfetol Hcl | 17 | $28,040 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $18,664 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $14,915 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 72 | $11,943 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,601 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $9,274 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $8,850 |
| Qvar RedihalerBeclomethasone Dipropionate | 22 | $8,721 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 226 | $6,805 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 28 | $4,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $101 | $129,346134 claims |
| Axsome Therapeutics, Inc.Sunosi | $171 | $28,04017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 93 critical care medicine providers in South Carolina.
Other critical care medicine in Charleston
- Charlton StrangeCharleston$205K
- Rahul ArgulaCharleston$186K
- James CarswellCharleston$159K
- Nicholas FoxCharleston$88K
- Christopher GilbertCharleston$44K
- Gregory SquiresCharleston$14K
- John MitchellCharleston$10K
- Luca PaolettiCharleston$5K
- Jennings NestorCharleston$5K
- Tatsiana BeikoCharleston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.